en · de · es · fr · pt
cjc-1295-notes.peptides6908.com › Info › Mechanism And Pharmacokinetics — Hands-On Walkthrough

Mechanism And Pharmacokinetics — Hands-On Walkthrough

By Editorial Desk · published 2025-08-11 · last reviewed 2025-09-03 · Info

Everything below concerns GHRH analogue. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2025-09-03. Where a claim depends on a specific study, the study is described rather than over-claimed.

Mechanism and Pharmacokinetics

Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.

The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.

Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.

Structure And Receptor Pharmacology

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.

Cjc-1295 at a glance

PropertyValueNotes
Target receptorGHRH receptor (GHRHR)Expressed on pituitary somatotrophs
Primary actionStimulates growth hormone releaseAmplifies pulse size
Half-life, albumin-binding formSeveral days as reportedSlow release from albumin complex
Half-life, unmodified analogAbout 30 minutes in animal estimatesCleared by proteases and filtration
Common analytical approachLC-MS/MS for peptide, immunoassay for hormonesMethods answer different questions

Receptor Action and Pharmacokinetics

CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.

The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.

Related pages on this site

CJC-1295 Structure And Mechanism

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Molecular Background and Naming

CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.

Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.

Supporting material

=== Class I === Class I fusion proteins resemble influenzavirus hemagglutinin in their structure. Post-fusion, the active site has a trimer of α-helical coiled-coils. The binding domain is rich in α-helices and hydrophobic fusion peptides located near the N-terminus (some examples show internal fusion peptides, however). Fusion conformation change can often be controlled by pH.

The epidermis is the strong, superficial layer that serves as the first line of protection against the outer environment. The human epidermis is composed of stratified squamous epithelial cells, which further break down into four to five layers: the stratum corneum, stratum granulosum, stratum spinosum and stratum basale. Where the skin is thicker, such as in the palms and soles, there is an extra layer of skin between the stratum corneum and the stratum granulosum called the stratum lucidum. The epidermis is regenerated from the stem cells found in the basal layer that develop into the corneum. The epidermis itself is devoid of blood supply and draws its nutrition from its underlying dermis. Its main functions are protection, absorption of nutrients, and homeostasis. In structure, it consists of a keratinized stratified squamous epithelium; four types of cells: keratinocytes, melanocytes, Merkel cells, and Langerhans cells. The predominant cell keratinocyte, which produces keratin, a fibrous protein that aids in skin protection, is responsible for the formation of the epidermal water barrier by making and secreting lipids. The majority of the skin on the human body is keratinized, with the exception of the lining of mucous membranes, such as the inside of the mouth. Non-keratinized cells allow water to "stay" atop the structure. The protein keratin stiffens epidermal tissue to form fingernails. Nails grow from a thin area called the nail matrix at an average of 1 mm per week.

==== Conductivity/resistivity ==== In ultra-pure water systems, electrolytic conductivity or resistivity, which are reciprocals of each other, is used as a general indicator of water purity. Absolutely pure water has a conductivity of 0.05501 μS/cm and a resistivity of 18.18 MΩ⋅cm at 25 °C, and ultra-pure water is typically specified to approach or meet this target. Resistivity is highly sensitive to contamination by ions, and 0.1 ppb of sodium chloride decreases the resistivity to 18.11 MΩ⋅cm (equivalent to 0.05523 μS/cm). Ultrapure water is easily contaminated by traces of carbon dioxide from the atmosphere passing through tiny leaks or diffusing through thin wall polymer tubing when sample lines are used for measurement. Carbon dioxide forms conductive carbonic acid in water which dissociates into H+ and bicarbonate. For this reason, conductivity probes are often used to provide continuous monitoring of conductivity/resistivity to ensure purity.

Sources: en.wikipedia.org

Supporting material

Damaged DNA – Over-exposure to UV radiation during preparation of DNA for ligation can damage the DNA and significantly reduce transformation efficiency. A higher-wavelength UV radiation (365 nm) which cause less damage to DNA should be used if it is necessary work for work on the DNA on a UV transilluminator for an extended period of time. Addition of cytidine or guanosine to the electrophoresis buffer at 1 mM concentration however may protect the DNA from damage. Incorrect usage of CIAP or its inefficient inactivation or removal. Excessive amount of DNA used. Incomplete DNA digest – The vector DNA that is incompletely digested will give rise to a high background, and this may be checked by doing a ligation without insert as a control. Insert that is not completely digested will also not ligate properly and circularize. When digesting a PCR product, make sure that sufficient extra bases have been added to the 5'-ends of the oligonucleotides used for PCR as many restriction enzymes require a minimum number of extra basepairs for efficient digest. The information on the minimum basepair required is available from restriction enzyme suppliers such as in the catalog of New England Biolabs. Incomplete ligation – Blunt-ends DNA (e.g. SmaI) and some sticky-ends DNA (e.g. NdeI) that have low-melting temperature require more ligase and longer incubation time. Protein expressed from ligated gene insert is toxic to cells. Homologous sequence in insert to sequence in plasmid DNA resulting in deletion. High concentration of EDTA or salts that acts as an inhibitors.

Not all cnidarians reproduce sexually, but many species have complex life cycles of asexual polyp stages and sexual medusae stages. Some, however, omit either the polyp or the medusa stage, and the parasitic classes evolved to have neither form. Cnidarians were formerly grouped with ctenophores, also known as comb jellies, in the phylum Coelenterata, but increasing awareness of their differences caused them to be placed in separate phyla. Most cnidarians are classified into four main groups: the almost wholly sessile Anthozoa (sea anemones, corals, sea pens); swimming Scyphozoa (jellyfish); Cubozoa (box jellies); and Hydrozoa (a diverse group that includes all the freshwater cnidarians as well as many marine forms, and which has both sessile members, such as Hydra, and colonial swimmers (such as the Portuguese man o' war). Staurozoa have recently been recognised as a class in their own right rather than a sub-group of Scyphozoa, and the highly derived parasitic Myxozoa and Polypodiozoa were firmly recognized as cnidarians only in 2007. Most cnidarians prey on organisms ranging in size from plankton to animals several times larger than themselves, but many obtain much of their nutrition from symbiotic dinoflagellates, and a few are parasites. Many are preyed on by other animals including starfish, sea slugs, fish, turtles, and even other cnidarians. Many scleractinian corals—which form the structural foundation for coral reefs—possess polyps that are filled with symbiotic photo-synthetic zooxanthellae.

The board of governors is the ultimate governing body of LLNS and is charged with overseeing the affairs of LLNS in its operations and management of LLNL. LLNS managers and employees who work at LLNL, up to and including the president and laboratory director, are generally referred to as laboratory employees. All laboratory employees report directly or indirectly to the LLNS president. While most of the work performed by LLNL is funded by the federal government, laboratory employees are paid by LLNS, which is responsible for all aspects of their employment, including providing health care benefits and retirement programs. Within the board of governors, authority resides in the executive committee to exercise all rights, powers, and authorities of LLNS, excepting only certain decisions that are reserved to the parent companies. The LLNS executive committee is free to appoint officers or other managers of LLNS and LLNL, and may delegate its authorities as it deems appropriate to such officers, employees, or other representatives of LLNS/LLNL. The executive committee may also retain auditors, attorneys, or other professionals as necessary. For the most part the executive committee has appointed senior managers at LLNL as the primary officers of LLNS. As a practical matter most operational decisions are delegated to the president of LLNS, who is also the laboratory director.

Sources: en.wikipedia.org

Frequently asked questions

How long does the albumin-binding form remain active?

Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.

What do researchers measure after administering the peptide?

Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.

Are the clinical effects well established?

Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

Network